PPIDT00006
Drug Information
| Name | Bivalirudin |
|---|---|
| Sequence | fPRPGGGGNGDFEEIPEEYL |
| DrugBank_ID | DB00006 |
| Type | small molecule |
| Indication | For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned. |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, lyophilized, for solution | Intravenous |
250 mg/1
|
| Injection, solution | Intravenous |
250 mg/1
|
| Injection, powder, lyophilized, for solution | Intravenous |
25000000 mg
|
| — | Intravenous |
250 mg
|
| Injection, powder, for solution | Intravenous bolus |
250 MG
|
| Injection, powder, lyophilized, for solution | Intravenous |
|
| Injection | Intracavernous |
250 mg/1
|
| Injection | Intravenous |
250 mg/1
|
| Injection, powder, lyophilized, for solution | Intravenous |
250 mg/5mL
|
| Injection, powder, lyophilized, for suspension | Intravenous |
250 mg/1
|
| Injection, solution, concentrate | Intravenous |
250 mg
|
| Powder, for solution | Intravenous |
250 mg / vial
|
| Injection | Intravenous |
250 mg/50mL
|
| Injection | Intravenous |
500 mg/100mL
|
| Solution | Intravenous |
5 mg / mL
|
| Injection, solution | Intravenous |
5 mg/1mL
|
| Powder | Intravenous |
250 MG
|
| Powder | Intravenous |
|